

REMARKS

Reconsideration of this application is respectfully requested. Claims 62, 63, and 65-70 have been canceled without prejudice. Claims 71 and 72 have been added. Support for these claims is found at, for example, page 3, lines 1-2 and 26-28, page 5, lines 4-7, page 8, lines 16-17, page 9, line 32, and Example 4 (pages 14-15) of the specification. Claims 29, 71, and 72 are pending. As claim 29 has been allowed, only claims 71 and 72 are at issue.

Claims 29 and 62-66 stand rejected under 35 U.S.C. §112, first paragraph, for failing to comply with the written description requirement. The Examiner contends that there is insufficient written description support for the terms human growth hormones, recombinant human growth hormones, parathyroid hormone, and fragments of parathyroid hormone.

While applicants respectfully disagree, in order to expedite prosecution of this application, these terms have been removed from the claims. New claims 71 and 72 only recite the active agent calcitonin. Accordingly, applicants respectfully request withdrawal of this rejection.

In view of the above amendments and remarks, it is respectfully requested that the application be reconsidered and that all pending claims be allowed and the case passed to issue.

If there are any other issues remaining, which the Examiner believes could be resolved through either a Supplemental Response or an Examiner's Amendment, the Examiner is respectfully requested to contact the undersigned at the telephone number indicated below.

October 31, 2007

Respectfully submitted,

By /Jay P. Lessler/
Jay P. Lessler
Registration No.: 41,151
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant